Future studies should focus on understanding isoform-specific functions in both the tumor and immune cells, which will have critical implications for developing therapeutic strategies that target either specific C/EBPβ isoforms, such as LIP, or C/EBPβ-induced target pathways. This evidence concerns the gene CEBPB and neoplasm.